
Zug – Switzerland, 13 October 2026 – NeuroGyn AG has successfully closed a CHF 4 million Series A financing round, led by a Swiss institutional investor active in the medical technology sector, alongside private investors.
The financing will support the initiation of human clinical studies, advance regulatory development, and move the company’s proprietary PosStim™ neuromodulation platform toward commercialization.
“For more than twenty years, I have seen patients with pelvic nerve disorders who struggled to find answers and suitable treatment options. This financing allows us to take PosStim into human clinical studies and generate the evidence needed to assess its potential to make pelvic neuromodulation accessible to many more women,” said Professor Marc Possover, founder of NeuroGyn.
Pelvic neuromodulation in women’s health
Founded by Professor Marc Possover, pioneer of pelvic nerve surgery and founder of neuropelveology, NeuroGyn builds on years of clinical experience and scientific research in this field dedicated to pelvic nerves and their disorders.
The company grew from a specific clinical ambition: to make minimally invasive pelvic neuromodulation accessible to gynecologists and, through them, to more women affected by pelvic organ dysfunction.
The PosStim platform has been developed around the Genital Nerve Stimulation (GNS) procedure, with overactive bladder as the initial clinical focus.
Advancing pelvic bioelectronic medicine
Women’s health is NeuroGyn’s initial clinical focus. Its broader vision is to advance pelvic bioelectronic medicine, exploring potential future applications for women and men, including male erectile dysfunction and pelvic pain. These applications will require dedicated clinical evaluation.
This financing provides the resources for the next stage: generating rigorous evidence to assess the platform’s safety and clinical performance while progressing along its regulatory pathway.
NeuroGyn sincerely thanks its investors for their trust, its team and development partners for their commitment, and Borel & Barbey – particularly Pierre Turrettini and Raoul de Montpellier – for their legal guidance throughout the transaction.
Read the announcement by Borel & Barbey
About NeuroGyn AG
NeuroGyn AG is a Swiss medical technology company based in Zug, Switzerland, developing the PosStim™ platform for minimally invasive pelvic neuromodulation. Founded by Professor Marc Possover, the company builds on clinical and scientific expertise in neuropelveology to advance pelvic bioelectronic medicine, with an initial focus on women’s health.
The PosStim platform is investigational, is not approved, and is not available for sale.